Hazard Information | Back Directory | [Biological Activity]
Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2. As of May 2017, it is in Phase II clinical trials for the treatment of diabetic macular edema. |
|
Company Name: |
Biolab Reagents
|
Tel: |
027-65279366 18162686757 |
Website: |
www.biolabreagent.com/ |
|